JMIR Publications

ABSTRACT

Background:

Heart failure is associated with significant morbidity and mortality. Metabolic abnormalities are known to occur in heart failure and hence can be used to identify individuals at risk of developing and managing patients with chronic heart failure. Their use may also ensure personalized therapy. Studies on the metabolic changes in heart failure and synthesis are needed.

Objective:

This scoping review aimed to systematically appraise the literature on metabolic changes in patients with heart failure and describe the knowledge gap to inform future targeted research that will help optimize their usefulness in patients with heart failure.

Methods:

This scoping review will be based on the strategy developed by Arskey and O’Malley and Levac et al. and updated by the Joanna Briggs Institute. A comprehensive search of the keywords “Heart Failure,” “myocardial failure,” “Metabolomes,” “Metabonomic,” and “Analytical Chemistry Technique” will be conducted in four electronic databases (MEDLINE, EBSCOhost, Scopus, and Web of Science. We will include original peer-reviewed research articles (clinical studies conducted on humans and systematic reviews, with or without a meta-analysis) published between January 2010 and December 2022. We will exclude studies that included patients with heart failure below 18 years of age and those not published in English. Two authors (UGA and MB) will independently search and screen the titles and abstracts and perform a full-text screen of the relevant and eligible articles. Relevant data will be extracted and synthesized. A third author or group will help resolve discrepancies in cases of inconsistencies.

Results:

The findings will be presented in a descriptive and narrative format with tabular and graphical displays. The results will be presented in a scoping review in due course, presented at relevant professional conferences and published in a peer-reviewed open-access journal.

Conclusions:

This scoping review will collate the available evidence to enhance our understanding of metabolic changes in patients with heart failure. It will also identify the most suitable and commonly used sample, analytical method, and specific metabolomes to facilitate standardization, reproducibility of results, and application in diagnosing, treating, and risk stratification of patients with heart failure. Furthermore, we hope the result will stimulate further research into metabolomes in patients with heart failure in low-and middle-income countries. Clinical Trial: https://osf.io/sp6xj